

DAFTAR PUSTAKA

1. Sawyers CL. Chronic myeloid leukemia. *N Engl J Med.* 1999; 340: 1330-40.
2. Fadjari H, Sukrisman L. Leukemia granulositik kronis, editors: Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta; Pusat Penerbitan Departemen Ilmu Penyakit Dalam FK UI; 2014: 2678-81.
3. Darji AA, Bharadia DP. Chronic myelogenous leukemia: a review and update of current and future therapy. *Int J. Pharm Sci.* 2016; 8(7): 35-46.
4. Goldman JM, Melo JV. Mechanisms of disease chronic myeloid leukemia-advances in biology and new approaches to treatment. *N Engl J Med.* 2003; 359: 1451-64.
5. Tashfeen S, Ahmed S, Bhatti FA, Ali N. Real time polymerase chain reaction in diagnosis of chronic myeloid leukemia. *Journal coll physicians surg pak.* 2014; 24(3): 190-3.
6. Hoglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukemia: an update. *Ann Hematol.* 2015; 2; 241-7.
7. NCCN. Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia. version (1). 2017. *National Comprehensive Cancer Network.* September 2016.
8. Hoffmaans VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D *et al.* The eutos population-based registry: incidence and clinical characteristics of 2904 cml patients in 20 european countries. *Leukemia.* 2015; 29: 1336-43.
9. Reksodiputro AH, Tadjoedin H, Supandiman I, Acang N, Kar AS, Benyamin AF *et al.* Epidemiology study and mutation profile of patients with chronic myeloid leukemia (CML) in indonesia. *J Blood Transfus.* 2015; 6: 1-13.
10. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment option in chronic myeloid leukemia. *American Cancer Society.* 2007; 11: 2171-81.
11. Vlahovic G, Crawford J. Activation of tyrosine kinase in cancer. *The oncologist.* 2003; 8: 531-8.
12. Talwar V, Saha R. Chronic myeloid leukemia: overview and recent advances. *Medicine Update.* 2010; 20: 609-12.
13. Fadel S, Taplaz M, Estrov Z, Kartajian HM. Chronic myelogenous leukemia: biology and therapy. *Ann Intern Med.* 1999; 131: 207-19.
14. Mesa RA, Elliott MA, Tefferi A. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. *Blood Reviews.* 2000; 14: 121-9.

15. Hamad A, Sahli Z, Sabban EM, Mouteirik M, Nasr R. Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. *Hindawi publishing corporations*. 2013; 1-13.
16. Forrest DL, Jiang X, Eaves CJ, Smith CL. An approach to the management of chronic myeloid leukemia in british columbia. *Current Oncology*. 2008; 2: 90-7.
17. Druker B, Lydon N. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. *J Clin Invest*. 2000; 105: 3-7.
18. Novartis Package literature for gleevec. East Hanover: Novartis Pharmaceuticls Corporation; 2002. Available at: <http://www.pharma.us.novartis.com/product/pi/pd/Gleevec.pdf>
19. Panigrahi I, Naithani R. Imatinib mesylate: a designer drug. *JAPI*. 2006; 54: 203-6.
20. KEPMENKES RI Nomor HK. 02. 02/MENKES/223/2014. Tentang : Harga obat sitostatika. Menteri Kesehatan Republik Indonesia. 2014.
21. Irazabal PM, Valls TA, Perez ON. Adverse skin effects of imatinib, a tyrosine kinase inhibitor. *Actas Dermosifiliogr*. 2014; 105(7): 655-62.
22. Walker I, Makarski J, Stevens A, Meyer RM and members of the Hematology Disease Site Group. Treatment of Chronic Myeloid Leukemia with Imatinib. Practice Guideline Report #6-15. Program In Evidence-Based Care. A Cancer Care Ontario Program. 2004.
23. O'Brien S, Berman E, Moore OJ, Ibarz PJ, Radich PJ, Shami JP et al. NCCN task force report: tyrosine kinase inhibitor therapy selection in the management of patient's with chronic myelogenous leukemia. *Journal of the National Comprehensive Cancer Network*. 2011; 9: 1-25.
24. Bhamidipati KP, Kantarjian HM, Cortes J, Cornelison MA, Jabbour E. Management of imatinib-resistance patient's with chronic myeloid leukemia. *Ther Adv Hematol*. 2013; 4(2): 103-17.
25. Lavallade HD, Apperley JF. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention to treat analysis. *Hematology Am Soc Hematol Educ Program*. 2008; 26(20): 3358-63.
26. Talati C, Ontiveros PE, Griffiths AE, Wang SE, Wetzler M. How we will treat chronic myeloid leukemia in 2016. *Blood Rev*. 2015; 2: 137-42.
27. Cardama QA, Hagop M, Kantarjian HM, Cortes EJ. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. *Cancer Control*. Departement of Leukemia at The University of Texas. 2009; 2: 122-31.
28. Ramirez P, Dipersio FJ. Therapy options in imatinib failures. *The Oncologist Journal*. 2008; 13: 424-34.

29. Galinsky I, Buchanan S. Guide to interpreting disease responses in chronic myeloid leukemia. *J Adv Pract Oncol.* 2012; 3: 225-36.
30. Bollmann WP, Giglio DA. Chronic myeloid leukemia: past, present, future. hematology and bone marrow transplantation. Hospital Israelita Albert Einstein-HIAE-Sao Paulo. Brazil. 2011; 9: 236-43.
31. Oehler GV. Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice. *American Society Hematology.* 2013; 176-83.
32. Marun EJ, Branford S. Current developments in molecular monitoring in chronic myeloid leukemia. *Ther Adv Hematol.* 2016; 7(5): 237-51.
33. El-Metnawy WH, Mattar MM, El-Nahass YH, Samra MA, Abdelhamid HM, Abdul RM et al. Predictive value of pretreatment bcr-abl transcript level on response to imatinib therapy in Egyptian patients with chronic phase chronic myeloid leukemia. *Int J Biomed Sci.* 2013; 9: 48-53.
34. Kagita S, Jiwtani S, Uppalapati S, Linga VG, Gundeti S, Digumarti R. Early molecular response in chronic myeloid leukemia patients predicts future response status. *Tumor Biol.* 2014; 35(5): 4443-6.
35. Yeung TD, Mauro JM. Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. *American Society of Hematology.* 2014: 240-3.
36. Chikkodi SV, Malhotra P, Naseem S, Khadwal A, Prakash G, Sahu KK et al. Factor affecting early molecular response in chronic myeloid leukemia. *Clinical Lymphoma, Myeloma & Leukemia.* 2015; 15: S114-9.
37. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al: Prognostic discrimination in “good risk” chronic granulocytic leukemia. *Blood.* 1984; 63: 789-99.
38. Braga GW, Chauffaille MD, Moncau JC, Souto EX, Silva MR, Kerbauy J. Chronic myeloid leukemia (CML): prognostic factors and survival analysis. *Sao Paulo Medical Journal.* 1996; 114(1): 1083-90.
39. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Manerro GG, Faderl F. Imatinib mesylate therapy in newly diagnosed patients with philadelphias chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. *Blood.* 2003;101: 97-100.
40. Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwizer D, Rosti G. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. *Blood.* 2014; 123: 1353-60.

41. An X, Tiwari KA, Sun Y, Ding RP, Ashby RC, Chen SZ. Bcr-abl tyrosine kinase inhibitor in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. *Leukemia research*. 2010; 34: 1255-68.
42. Kurzrock R, Kantarjian MH, Druker JB, Taplaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. *Ann Intern Med*. 2003; 138: 819-30.
43. Deininger WN, Goldman MJ, Melo VJ. The molecular biology of chronic myeloid leukemia. Departement of Hematology Oncology. University of Leipzig. Germany. 2000; 3343-56.
44. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. *N Engl J Med*. 1999; 341(3): 164-72.
45. Frazer R, Irvine EA, McMullin FM. Chronic myeloid leukemia in the 21st century. *Ulster Med J*. 2007; 1: 8-17.
46. Kartarjian HM, Taplaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. *Ann Intern Med*. 2006; 145: 913-23.
47. Thielen N, Ossenkoppele GJ, Schuurhuis GJ, Janseen MW. New insights into the pathogenesis of chronic myeloid leukemia: towards a path to cure. *Journal of medicine*. 2011; 69(10): 430-40.
48. Bacco AB, Keeshan K, Mckenna SL, Cotter TG. Molecular abnormalities in chronic myelogenous leukemia: deregulation of cell growth and apoptosis. *The Oncologist*. 2000; 5: 405-15.
49. Sulivan C, Peng C, Chen Y, Li D, Li S. Targeted therapy of chronic myeloid leukemia. *Biochem pharmacol*. 2010; 80(5): 584-91.
50. Ahmed W, Etten VA. Signal transduction in the chronic leukemias: implications for targeted therapies. *Curr Hematol Malig Rep*. 2013; 8: 71-80.
51. Tortorella MS, Hung A, Karagianis CT. The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia. *Antioxid. Redox signal*. 2015; 22: 1425-62.
52. O'Dwyer M. Multifaceted approach to the treatment of bcr-abl positive leukemias. *The oncologist*. 2002; (1): 30-8.
53. Sessions J. Chronic myeloid leukemia in 2007. *J Manag Care Pharm*. 2007; 13(8): S4-7.
54. Manero GG, Faderl S, O'Brien S, Cortes J, Taplaz M, Kartarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. *American Cancer Society*. 2003: 437-57.

55. Tohami T, Nagler A, Amariglio N. Laboratory tools for diagnosis and monitoring response in patients with chronic myeloid leukemia. *IMAJ*. 2012; 14: 501-7.
56. Mondal DJ, Tewary D, Sardar MS. Chronic myloid leukemia-an overview. *International Journal of Science and Research*. 2014; 3: 128-32.
57. Bauer S, Romvari E, Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia. *J Adv Pract Oncol*. 2012; 3: 151-60.
58. Ruibao R. Mechanisms of bcr-abl in the pathogenesis of chronic myelogenous leukaemia. Rosenstiel Basic Medical Sciences Research Center. Brandeis University. 2003; 5: 172-83.
59. Apperley FJ. Chronic myeloid leukaemia. Departement of Haematology. Imperial College London. UK. *Lancet*. 2015; 385: 1447-59.
60. Hasford J, Bacarrani M, Hoffman V: Predicting complete cytogenetic response and subsequent progression free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. *Blood*. 2011; 118: 686-92.
61. Dasgupta A, Kumar L. Chronic myeloid leukaemia: a paradigm shift in management. *The National Medical Journal of India*. 2014; 6: 316-23.
62. Xia L, Qian W, Yang M, Li Q, Liu F, Xie Y. Comparison of the utility and applicability of the sokal, hasford and eutos scores in a population of chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy. *Oncotargets and therapy*. 2015; 8: 2485-92.
63. Yamamoto E, Fujisawa S, Hagiwara M, Tanaka M, Fujimaki K, Kishimoto K et al. European Treatment and outcome study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. *Cancer Sci*. 2014; 105: 105-9.
64. Kuntegowdanahalli CL, Kanakasetty BG, Thanky HA, Dasappa L, Jacob AL, Mallekavu BS et al. Prognostic and predictive implications of sokal, euro and eutos scores in chronic myeloid leukaemia in the imatinib era-experience from a tertiary oncology centre in souther india. *Ecancer*. 2016; 10: 679-89.
65. David G, Savage MD, Karen H, Antman MD. Imatinib mesylate-a new oral targeted therapy. *N Engl J Med*. 2002; 9: 683-93.
66. Druker BJ, Talpaz M, Resta JD, Peng B, Buchdunger E, Ford MJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. *N Engl J Med*. 2001; 344: 1031-7.
67. Patel D, Suthar PM, Patel V, Singh R. BCR ABL Kinase Inhibitors for Cancer Therapy. *International Journal of Pharmaceutical Sciences and Drug Research* 2010; 2(2): 80-90.
68. Sacha T. Imatinib in Chronic Myeloid Leukemia: an Overview. *Mediterr J Hematol Infect Dis*. 2014; 6: 1-9.

69. David W, Woessner BA, Carol SL, Michael WD. Development of an effective therapy for cml. *Cancer J.* 2011; 6: 477-86.
70. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. *Science.* 2000; 289: 1938-42.
71. Mauro MJ, Druker BJ. STI571: Targetng bcr-abl as therapy for cml. *The Oncologist.* 2001; 6: 233-8.
72. Jabbour E, Cortes EJ, Ghanem H, O'Brien S, Kantarjian MH. Targeted therapy in chronic myeloid leukemia. *Expert Rev. Anticancer Ther.* 2008; 8(1): 99-110.
73. Lopez-Hernandes MA, Ibarra MA, Gonzalez-Avante CM. Overall survival of chronic myeloid leukemia patients treated with related donor hematopoietic stem cell transplant or imatinib. *Rev Invest Clin.* 2011; 63(5): 494-99.
74. Baccarani M. Initial treatment for patients with chronic myeloid leukemia. *Leukemia Supplements.* 2012; 1: S37-9.
75. Jain P, Das VNR, Ranjan A, Chaudhary R, Pandey K. Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated wiyh imatinib or hydroxyurea. *Journal of Research in Pharmacy Practice.* 2013; 2(4): 156-61.
76. Cortes J, Cardama QA, Kartarjian HM. Monitoring moleculer respon in chronic myeloid leukemia. *Cancer.* 2011; 117(6): 1113-22.
77. Baccarani M, Cortes J, Pane F. Chronic myeloid leukemia: an update of concepts and management recommendations of european leukemiaNet. *J Clin Oncol.* 2009; 27: 6041-51.
78. Kantarjian HM, O'Brien S, Cortes JE. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. *Cancer.* 2003; 97: 1033-41.
79. Shah PN, Ageno S. Changing therapy in tki-resistant chronic myeloid leukemia. *Clinical Advances in Hematology & Oncology.* 2014; 13: 7-11.
80. Kantarjian HM, O'Brien S, Shan J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions. *Cancer.* 2008; 112: 837-45.
81. Al-Dewik IN, Jewel PA, Yassin AM, El-Ayoubi RH, Morsi MH. Molecular monitoring of patients with chronic myeloid leukemia (CML) in the state of Qatar: optimization of techniques and response to imatinib. *Science connect.* 2014; 24: 1-11.
82. Zhen C, Wang LY. Molecular monitoring of chronic myeloid leukemia international standardization of bcr-abl1 quantitation. *J Mol Diagn.* 2013; 15: 556-64.

83. Hughes PT, Kaeda J, Branford S. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. *N Engl J Med.* 2003; 349: 1423-32.
84. Deininger MW. Milestones and monitoring in patients with cml treated with imatinib. *American Society Hematology.* 2008: 419-26.
85. Guilhot F, Larson RA, O'Brien SG, Gathmann I, Druker BJ. Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy. *Blood.* 2007; 110-6.
86. Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L *et al.* Combinating bcr-abl transcript levels at 3 and 6 months in chronic myeloid leukemia: Implications for early intervention strategies. *Blood.* 2013; 121: 2739-42.
87. Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the european leukemianet recomendations for the management of cml. *Ann Hematol.* 2015; 94(2): 141-7.
88. Eide AC, O'Hare T. Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. *Curr Hematol Malig Rep.* 2015; 10: 158-66.
89. Soverini S, Hochhaus A, Nicollini FE, Gruber F, Lange T, Saglio G. Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: an expert panel on behalf of recomendations from european leukemiaNet. *Blood.* 2011; 118: 1208-15.
90. Bixby D, Taplaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. *American Society of Hematology.* 2009: 461-76.
91. Jabbour E, Parikh AS, Kantarjian HM, Cortes HJ. Chronic myeloid leukemia-mechanisms of resistance and treatment. *Hematol Oncol Clin North Am.* 2011;(5):1-17.
92. Harnicar S, Mathew S. Spotlight on nilotinib in the treatment of chronic myelogenous leukemia. *Blood and Lymphatic Cancer: Targets and Therapy.* 2014; 4: 61-7.
93. Miller DG, Bruno JB, Lim SC. Resistant mutations in cml and ph+ all-role of ponatinib. *Biologics Target and Therapy.* 2014; 8: 243-54.
94. Yahng SA, Jang EJ, Choi SY, Lee SE, Kim SH, Kim DW. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of sokal, euro, and eutos scores in korea population. *Int J Hematol.* 2014: 1-9.
95. Dybko J, Jazwiec B, Haus O, Kujda DU, Slowik KK, Wrobel T *et al.* The hasford score may predict molecular response in chronic myeloid leukemia patients: a single institution experience. *Disease markers.* 2016: 1-5.

96. Bee PC, Sekaran V, Jie RR, Kweh TY, Gan GG. The predictive value of early molecular response in chronic myeloid leukemia patients treated with imatinib in a single real-world medical centre in a developing country. *Singapore Med J.* 2017; 58(3): 150-4.
97. Eskazan AE, Sadri S, Keskin D, Ayer M, Kantarcio glu B, Demirel N *et al.* Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and glivec. *Clinical Lymphoma, myeloma & leukemia. Elsevier.* 2017; 1-8.
98. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin.* 2011; 61(2): 69-90.
99. Ibrahim ME, Osman EA. Myeloid leukemia : a molecular focus on etiology and risk within Africa. International Centre of Genetic Engineering and Biotechnology. 2015; 23: 465-84.
100. Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C *et al.* Early reduction of bcr-abl mRNA transcript levels predicts cytogenetic response in chronic phase cml patients treated with imatinib after failure of interferon alfa. *Nature.* 2002; 16: 1579-83.
101. Bonecker S, Magnago M, Kaeda J, Solza C, Renault IZ. Is the Bcr-Abl/gusb transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib. *Rev Bras Hematol Hemoter.* 2015; 37(2): 142-3.
102. Deb P, Chakrabarti P, Chakrabarty S, Aich R, Nath U, Ray SS *et al.* Incidence of bcr-abl transcript variants in patients with chronic myeloid leukemia: their correlation with presenting features, risk score and response to treatment with imatinib mesylate. *Indian Journal of Medical Oncology.* 2014; 35(1): 26-30.
103. Lemos JAR, Oliveira CM, Scerni ACC, Bentes AQ, Beltrao AC, Bentes IRG *et al.* Differential molecular response of the transcripts b2a2 and b3a2 to imatinib mesylate in chronic myeloid leukemia. *Genetics and molecular research.* 2005; 4(4): 803-11.
104. Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F *et al.* The bcr-abl1 transcript type influences response and outcome in Philadelphia chromosomepositive chronic myeloid leukemia patients treated frontline with imatinib. *American J of Hematol.* 2017; 92(8):797-805.
105. Jaruskova M, Curik N, Hercog R, Polivkova V, Motlova E, Benes V *et al.* Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment. *Journal of experimental and clinical research.* 2017; 36(55): 1-17.
106. Sung EL, Soo YC, Yun JO, Soo HK, Hye YS, Hea LY *et al.* Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia. *Elsivier.* 2015: 1-8.
107. Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G *et al.* Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. *Leukemia.* 2016; 30: 48-56.

108. Meissner R, Covas DT, Dias PM, Job F, Leite M, Nardi NB. Analysis of mRNA transcripts in chronic myeloid leukemia patients. *Genetic and molecular biology*. 1999; 22(4): 475-9.
109. Harrington P, Kizilors A, Lavallade HD. The role of early molecular response in the management of chronic phase cml. *Curr Hematol Malig Rep*. 2017; 12: 79-84.
110. Branford S, Yeung DT, Parker WT, Robers ND, Purins L, Braley JA *et al*. Prognosis for patients with cml and >10% bcr-abl1 after 3 months of imatinib depends on the rate of bcr-abl1 decline. *Blood*. 2014; 124(4): 511-8.
111. Millot F, Guilhot J, Barachel A, Petit A, Bertrand Y, Mazingue F *et al*. Impact of early molecular response in chronic myeloid leukemia treated in the French glivec phase 4 study. *Blood*. 2014; 124(15): 2408-10.
112. Ya-Zhen Q, Qian J, Hao J, Yue YL, Hong HZ, Yan RL *et al*. Combination of white blood cell count at presentation with molecular response at 3 months better predict deep molecular response to imatinib in newly diagnosed chronic phase chronic myeloid leukemia patients. *Medicine*. 2016; 95(2): 1-9.
113. Cortes J, Taplaz M, O'Brien S, Jones D, Luthra R, Shan J *et al*. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. *Clin Cancer Res*. 2005; 11(9): 3425-32.
114. Gomez GA, Sokal EJ, Walsh D. Prognostic features at diagnosis of chronic myeloid leukemia. *Cancer*. 1981; 47: 2470-7.

